rosiglitazone has been researched along with Pituitary Neoplasms in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gruszka, A; Kunert-Radek, J; Pawlikowski, M; Radek, M; Winczyk, K; Ławnicka, H | 1 |
| Acerbi, G; Bartalena, L; Bogazzi, F; Brogioni, S; Cecchetti, D; Cosci, C; Gasperi, M; Guida, C; Martino, E; Raggi, F; Russo, D; Ultimieri, F; Vanacore, R; Viacava, P | 1 |
| Atkinson, AB; Hull, SS; Sheridan, B | 1 |
| Gruszka, A; Kunert-Radek, J; Pawlikowski, M | 1 |
| Bonner, SE; Emery, MN; Galloway, M; Grossman, AB; Korbonits, M; Leontiou, C; Merulli, C; Musat, M; Nanzer, AM; Nikookam, K; Powell, M | 1 |
| Ince, P; Munir, A; Newell-Price, J; Ross, R; Song, F; Walters, SJ | 1 |
6 other study(ies) available for rosiglitazone and Pituitary Neoplasms
| Article | Year |
|---|---|
Effects of rosiglitazone--peroxisome proliferators-activated receptor gamma (PPARgamma) agonist on cell viability of human pituitary adenomas in vitro.
Topics: Acromegaly; Adenoma; Adrenocorticotropic Hormone; Adult; Aged; Cell Proliferation; Cell Survival; Drug Evaluation, Preclinical; Female; Human Growth Hormone; Humans; Hypoglycemic Agents; Male; Middle Aged; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Cells, Cultured | 2009 |
PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas.
Topics: Adenoma; Animals; Annexin A5; Apoptosis; Cell Line; DNA Fragmentation; Female; Gene Expression; Human Growth Hormone; Humans; Ligands; Mice; Mice, Nude; NIH 3T3 Cells; Pituitary Neoplasms; Promoter Regions, Genetic; Rats; Rats, Inbred WF; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transfection | 2004 |
Pre-operative medical therapy with rosiglitazone in two patients with newly diagnosed pituitary-dependent Cushing's syndrome.
Topics: Adult; Cushing Syndrome; Female; Humans; Middle Aged; Pituitary Neoplasms; Rosiglitazone; Thiazolidinediones | 2005 |
Rosiglitazone, PPAR-gamma receptor ligand, decreases the viability of rat prolactin-secreting pituitary tumor cells in vitro.
Topics: Animals; Carcinogens; Cell Survival; Diethylstilbestrol; Drug Implants; Hypoglycemic Agents; Ligands; Male; Pituitary Neoplasms; PPAR gamma; Prolactin; Rats; Rats, Inbred F344; Rosiglitazone; Thiazolidinediones; Tumor Cells, Cultured | 2005 |
PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Animals; Base Sequence; Case-Control Studies; Cell Line, Tumor; Cell Proliferation; Humans; Immunohistochemistry; Middle Aged; Molecular Sequence Data; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Pituitary Neoplasms; PPAR gamma; Rats; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones | 2006 |
Ineffectiveness of rosiglitazone therapy in Nelson's syndrome.
Topics: ACTH-Secreting Pituitary Adenoma; Adrenocorticotropic Hormone; Adult; Aged; Anti-Inflammatory Agents; Female; Fludrocortisone; Humans; Hydrocortisone; Hypoglycemic Agents; Magnetic Resonance Imaging; Male; Nelson Syndrome; Pancreatitis; Pituitary ACTH Hypersecretion; Pituitary Gland; Pituitary Neoplasms; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tomography, X-Ray Computed | 2007 |